

## HR 326

### Neuromyelitis Optica Consortium Act

**Congress:** 115 (2017–2019, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Jan 5, 2017

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Jan 25, 2017)

**Official Text:** <https://www.congress.gov/bill/115th-congress/house-bill/326>

### Sponsor

**Name:** Rep. Lee, Barbara [D-CA-13]

**Party:** Democratic • **State:** CA • **Chamber:** House

### Cosponsors

*No cosponsors are listed for this bill.*

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jan 25, 2017

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

*No related bills are listed.*

### Summary (as of Jan 5, 2017)

#### Neuromyelitis Optica Consortium Act

This bill amends the Public Health Service Act to require the National Institutes of Health to establish, administer, and coordinate a national consortium on neuromyelitis optica (NMO), which is a neurological disease that can cause blindness and paralysis. The consortium must:

- award grants for research on the causes of, and the risk factors and biomarkers associated with, NMO;
- assemble a panel of experts to provide guidance and recommendations on research design and protocols; and
- designate a central laboratory to collect and analyze data from this research and to make the data and analysis available to researchers.

## Actions Timeline

---

- **Jan 25, 2017:** Referred to the Subcommittee on Health.
- **Jan 5, 2017:** Introduced in House
- **Jan 5, 2017:** Referred to the House Committee on Energy and Commerce.